Observational studyRMD open2022

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry.

Hafsah Nabi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.